Phibro Animal Health Corp
NASDAQ:PAHC

Watchlist Manager
Phibro Animal Health Corp Logo
Phibro Animal Health Corp
NASDAQ:PAHC
Watchlist
Price: 38.28 USD -4.49%
Market Cap: 1.6B USD

Phibro Animal Health Corp
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Phibro Animal Health Corp
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Phibro Animal Health Corp
NASDAQ:PAHC
Operating Income
$168.5m
CAGR 3-Years
29%
CAGR 5-Years
19%
CAGR 10-Years
7%
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.9B
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$16.1B
CAGR 3-Years
11%
CAGR 5-Years
22%
CAGR 10-Years
19%
Pfizer Inc
NYSE:PFE
Operating Income
$18.3B
CAGR 3-Years
-23%
CAGR 5-Years
12%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Operating Income
$24.5B
CAGR 3-Years
7%
CAGR 5-Years
27%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Operating Income
$26.4B
CAGR 3-Years
46%
CAGR 5-Years
34%
CAGR 10-Years
22%
No Stocks Found

Phibro Animal Health Corp
Glance View

Market Cap
1.5B USD
Industry
Pharmaceuticals

Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 1,725 full-time employees. The company went IPO on 2014-04-11. The firm operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The firm develops, manufactures and markets a range of products for food animals, including poultry, swine, beef and dairy cattle, and aquaculture. The firm sells animal health and mineral nutrition products either directly to integrated poultry, swine and cattle producers or through commercial animal feed manufacturers, wholesalers and distributors. Its Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The firm's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.

PAHC Intrinsic Value
38.2 USD
Fairly Valued
Intrinsic Value
Price

See Also

What is Phibro Animal Health Corp's Operating Income?
Operating Income
168.5m USD

Based on the financial report for Sep 30, 2025, Phibro Animal Health Corp's Operating Income amounts to 168.5m USD.

What is Phibro Animal Health Corp's Operating Income growth rate?
Operating Income CAGR 10Y
7%

Over the last year, the Operating Income growth was 95%. The average annual Operating Income growth rates for Phibro Animal Health Corp have been 29% over the past three years , 19% over the past five years , and 7% over the past ten years .

Back to Top